CASTLE BIOSCIENCES INC (CSTL)
Castle Biosciences TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barretts Esophagus
Castle Biosciences TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barretts Esophagus
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business